Company Website:
http://www.robbinsarroyo.com
SAN DIEGO & BOSTON -- (Business Wire)
Shareholder rights law firm Robbins Arroyo LLP is investigating
whether certain officers and directors of Juniper Pharmaceuticals, Inc.
(NASDAQGS: JNP) violated federal securities laws by issuing materially
misleading information to the investing public. Juniper Pharmaceuticals
focuses on developing therapeutics that address unmet medical needs in
women's health.
Juniper Pharmaceuticals Announces Restatement of Financials
On October 24, 2016, Juniper Pharmaceuticals announced in its Form 8-K
filed with the U.S. Securities and Exchange Commission that it would
have to restate its financial statements since 2013. The company stated
that the errors concerned revenue recognition related to a supply
agreement with an affiliate of Germany's Merck KGaA. On this news,
Juniper Pharmaceuticals stock fell 10% in early morning trading on
October 25, 2016.
View this press release on the law firm's Shareholder Rights Blog: www.robbinsarroyo.com/shareholders-rights-blog/juniper-pharmaceuticals-inc
Juniper Pharmaceuticals Shareholders Have Legal Options
Concerned shareholders who would like more information about their
rights and potential remedies can contact attorney Darnell R. Donahue at
(800) 350-6003, DDonahue@robbinsarroyo.com,
or via the shareholder
information form on the firm's website.
Robbins Arroyo LLP is a nationally recognized leader in shareholder
rights law. The firm represents individual and institutional investors
in shareholder derivative and securities class action lawsuits, and has
helped its clients realize more than $1 billion of value for themselves
and the companies in which they have invested.
Attorney Advertising. Past results do not guarantee a similar outcome.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161026006973/en/
Contacts:
Robbins Arroyo LLP
Darnell R. Donahue
(619) 525-3990 or Toll
Free (800) 350-6003
DDonahue@robbinsarroyo.com
www.robbinsarroyo.com
Source: Robbins Arroyo LLP
© 2024 Canjex Publishing Ltd. All rights reserved.